Fintel on MSN
Piper Sandler downgrades IO Biotech (IOBT)
Fintel reports that on January 26, 2026, Piper Sandler downgraded their outlook for IO Biotech (NasdaqGS:IOBT) from Overweight to Neutral. Analyst Price Forecast Suggests 702.23% Upside As of January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results